fusion for diabetes therapy requires improved knowledge of subcutaneous insulin absorption kinetics. We have used kinetic modelling to quantitate systemic insulin delivery produced by subcutaneously-infused insulin (i.e. simulated meal and basal delivery). Profiles were studied in normal subjects, with endogenous insulin suppressed. Paired studies of intravenous insulin infusion enabled systemic insulin delivery to be quantitated. High rate subcutaneous delivery (10 U in 5 rain) resulted in a systemic delivery of approximately 8 U in 4 h. Increasing infused insulin concentration delayed systemic delivery (p < 0.025). Both continuous and pulsatile tow-rate infusions (2.4U/h) gave similar slow increases in systemic delivery to 1 U after 4 h. Computer fitting to a two-pool model of the subcutaneous space suggested a low rate of insulin degradation for all profiles (rate constant < 10%/h). We conclude that: (1) systemic insulin delivery following subcutaneous infusion conforms reasonably to a two-pool model, (2) subcutaneous insulin degradation is low regardless of input profile, (3) a long delay in basal systemic delivery should be taken into account when initiating or resuming interrupted subcutaneous insulin infusion. Kinetic modelling of subcutaneous insulin absorption should be useful to predict the impact of programming strategies for continuous subcutaneous insulin infusion therapy.
Widespread interest in continuous subcutaneous insulin infusion (CS II) for diabetes therapy has led to an interest in quantitation of absorption kinetics of subcutaneously-infused insulin. Processes such as local tissue accumulation versus degradation of insulin and time delays in systemic delivery rates need clarification. In addition the influence of concentration of infused insulin needs to be studied further. A kinetic model of these processes should have predictive value and aid in the further refinement of CSII.
Classic studies of subcutaneous insulin absorption have given us some knowledge in the area [1, 2] . However these studies were not performed with the aim of assessing the particular delivery patterns used with CSII and the methods then used are subject to problems of interpretation. Tracer studies of the disappearance of insulin from the injection site may not reflect true systemic insulin delivery rates of biologically active insulin in the presence of local tissue degradation of insulin [3] . In studies of CSH there is a paucity of data on serum insulin levels and where information is available [4] there is a problem of interpretation of free insulin levels in the presence of insulin antibodies.
In a previous study [5] , we proposed the use of a hypoglycaemic blood glucose clamp in normal subjects to create a situation in which endogenous insulin release is suppressed and serum insulin levels are directly related to the entry of subcutaneous insulin into the vascular system. In this and in a similar study, using somatostatin to block endogenous insulin secretion [6] , the object of insulin administration was simulation of the normal insulin response to a mixed meal. A wider range of subcutaneous insulin infusion profiles have now been studied and are reported here. In addition, we have applied kinetic modelling techniques to interpret the original data and new data. Our aims were to estimate the fate of subcutaneously administered insulin and its dependence on the infusion profile, and to relate our findings to the therapeutic application of CSII.
Subjects and methods

Subjects
Studies were performed on a total of ten normal subjects aged 20-24 years. All subjects were within 10% of their ideal body weight (Metropolitan Life Insurance Tables). The experimental protocol was approved by the Hospital Ethics Committee and possible risks were explained to all subjects before voluntary consent was obtained. Subjects were studied after an overnight fast.
General aspects of experimental studies
Insulin was delivered into the SC tissue of the anterior abdominal wall of normal subjects via a 25 gauge needle. Where insulin was delivered over a short time period (up to 30 rain) a protocol (designated protocol A) was followed as described previously [5] : that is, IV infusion of insulin at 1-1.4 U/h and glucose (variable rate) was used to clamp blood glucose between 2.5 and 3.0 mmol/l to suppress endogenous insulin release. This infusion, into the arm contralateral to that used for sampling, commenced 60 min before SC insulin and continued throughout the study. Serum immunoreactive insulin (IRI) increments above the plateau level created by the IV infusion were used to indicate absorption from the SC site, Where SC insulin was infused over a period of 4 h, the IV insulin infusion was omitted and interpretation of serum insulin levels was made only beyond the first hour (designated protocol B). In all studies, neutral highly-purified porcine insulin (Actrapid MC, 40 U/ml, Novo, Denmark) was used. Where necessary this was diluted using normal saline for SC infusion or using polygetine solution (Haemaccet, Hoechst-Bebringwerke, FRG) for IV infusion [7] by a peristaltic pump (Model 531, IVAC Corporation, California).
Specific experimental studies
Rapid SC delivery (simulated meal defive~). Ten units SC insulin were administered to four normal, non-obese, overnight-fasted subjects by constant infusion over 5 rain at a concentration of 40 U/ml. Protocol A was used to block endogenous insulin production. The studies were compared with similar, earlier studies on the same subjects where insulin was infused over 5 or 30min at a concentration of 3.3 U/ml [5] . Dilute insulin was administered first in three subjects, and last in one subject, witb an interval of 5-7 days between studies.
Pulsed versus continuous insulin delivery (simulated basal delivery).
Many insulin infusion devices deliver insulin in the basal mode as a series of small pulses rather than as a continuous infusion. To investigate whether pulsatile delivery alters absorption kinetics, insulin was infused SC at a rate of 2.4 U/b into six overnight-fasted subjects by continuous flow (40 U/ml, 60 p.l/h) orby pulsatile flow (40 U/ml, one I5 l.tl pulse every 15 rain) in paired studies on separate occasions. Most insulin infusion devices now available employ insulin delivery in the basal mode between these extremes. Serum insulin was measured over a 4-h period.
Systemic insulin distribution kinetics. Values of metabolic clearance rate (MCR) and total dist/ibution volume (TDV) of insulin are required in order to quantitate systemic appearance rates of SC insulin. To calculate these an additional IV infusion study was performed in subjects who previously received rapid SC delivery. An IV infusion profile was used ( Fig. 1 ) which produced serum insulin levels approximating those previously produced by rapid SC delivery. The IV profile, previously used by us for control of post-meal byperglycaemia by the IV route [8] , delivered 7.5 U over a 2-h period. The calculation of MCR and TDV over a range of insulin variation similar to that following rapid SC delivery was designed to minimise any possible departure from first order kinetics in systemic insulin distribution. The IV profile was superimposed on the constant insulin infusion of 1 U/h IV insulin (protocol A) used to suppress endogenous insulin secretion.
Theoretical studies
Two theoretical models were examined as an aid to interpreting experimental data, In the first a single pool (Fig.2) was envisaged for SC distribution of insulin; this assumes that a]l SC insulin is immedi- ately available for transcapillary absorption. As this assumption seemed an oversimplification a second, two-pool model of SC insulin distribution was proposed (Fig. 2) . Here insulin was assumed to move from a first to a second pool (perhaps in the vicinity of the capillary wall) before absorption. Our rationale was to seek a minimal model which would give a reasonable agreement with experimental data [9}. Both models assume a fractional rate of systemic delivery ksp and a degradation rate constant lq from the respective SC pool (the process labelled as "degradation" may include insulin which is irreversibly bound to SC tissue as well as insulin which is physically degraded; no distinction can be made mathematically between these possibilities). When protocol A was pursued an IV infusion of insulin constituted an additional entry into the plasma compaz~ment (not shown).
The mathematical formulae representing the theoretical models are as follows:
Model 2
where x is amount of SC insulin in single pool (Model 1), xl, x2 are amounts of SC insulin in pools 1 and 2 respectively (Model 2), k12, ka, k~p are rate constants as indicated in Figure 2 , S(t) and I(t) are SC and IV insulin infusion rates respectively, y is amount of insulin in the total distribution volume (TDV), and MCR is metabolic clearance rate of insulin. (For both models plasma insulin concentration C is given by C=y/TDV). The model properties were studied in two ways.
(a) General model behaviour was studied using a BASIC program incorporating a fourth order Runge-Kutta integration routine on a PDPll/03 computer (Digital Equipment Corporation, Maynard, Massachusetts, USA); (b) The models were fitted to experimental data using a Fortran nonlinear regression program (MODFIT) written for this type of application [101. The model equations were contained in a subroutine to MODFIT. This procedure gave estimates of the rate constants and pool masses of insulin following each SC insulin input profile and also an estimate of the time variation of systemic insulin appearance rate of SC insulin [equal to 1% x2 in Eq [5] ]. Note that calculation of systemic insulin appearance rate depends principally on the parameters MCR and TDV and similar rates are obtained using Models 1 and 2.
Analytical techniques
Blood glucose was estimated using a Yellow Springs 23 AM Glucose Analyser (Yellow Springs, Ohio, USA). Serum insulin and C-peptide were measured by radioimmunoassays using second antibody separation. Reagents for the C-peptide assay were supplied by the Novo Research Institute, Denmark [11] . Statistical levels of inference were determined using Student's ttest. Figure 1 shows the IV insulin infusion profile given to obtain quantitative estimates of MCR and TDV for systemic insulin distribution and clearance. This profile was added to a constant IV infusion of IU/h beginning 1 h previously which suppressed blood glucose from 5.0_+0.2 to 3.0_+0.1 mmol/1 and endogenous insulin secretion (C-peptide to <0.2 p~g/1) during the study. 
Results
Determination of metabolic clearance rate and total distribution volume
Additional SC infusion studies
Effect of concentration. Figure 3 shows the time profile obtained with 10U of 40 U/ml insulin infused over 5 min and compares this with the previously reported profile obtained with diluted insulin (3.3 U/ml) in the same subjects. There was a consistent delay of 15-30 min in serum insulin response to concentrated insulin, compared with that to dilute insulin. Areas under the insulin response curve above the plateau established by IV infusion were significantly greater over the period 0-60 min (p < 0.025) with dilute SC insulin (i. e. with increased volume of infusion), indicating faster absorption. The incremental areas from 0 to 240 min were, however, not significantly different, suggesting that SC insulin degradation was not strongly influenced by volume of infusion. Most of the variation in peak insulin responses and incremental areas in the SC studies at the two concentrations appeared related to between-subject, rather than within-subject, variation. There was a similar ranking from low to high responders in each case and paired differences in peak levels were < 10 mU/1 in three out of four subjects.
Prolonged low-level insulin infusion (simulated basal infusion
). An infusion rate of 2.4 U/h (40 U/ml) over 4 h was chosen to represent prolonged basal SC infusion. This was administered to the same six subjects on two occasions by continuous flow (40 U/ml, 60 p,1/h) or by pulsatile flow (40 U/ml, 15-bd pulse every 15 min). Serum insulin responses are shown in Figure 4 . After 4 h of SC infusion, blood glucose fell to 3.3 + 0.2 and 3.5 + 0.2 mmol/1 in the two studies respectively. Insulin levels rose slowly to reach 18_+4 and 22_+4mU/1 at 4 h for continuous and pulsatile delivery respectively, and in both cases C-peptide levels fell to negligible values (< 20% of basal). There was no significant difference 9 between the two studies in levels of insulin, C-peptide or blood glucose at any point. Figures 3 and 4 (continuous infusion), and to responses to an infusion of 10 U insulin over 30 rain as described previously [5] . Model rate constants for the best fit are shown. Lowest curve n =6, other curves n =4. Mean+ SEM shown
Kinetic analysis of SC-infused insulin
Computer fits to experimental responses. Models 1 and 2 s,'e applied to the analysis of data shown in Figures 3  and 4 . In addition previously-reported responses to 10 U insulin infused SC over 30 min (3.3 U/ml) were in- Computer-predicted systemic appearance rates of insulin for the four profiles shown in Figure 5 . Shown also are estimates of total systemic appearance of insulin delivered over a 4-h period (percentage of administered insulin)
cluded [5] . Because of the similarity in responses to continuous and pulsatile low-level insulin delivery only the former was subjected to analysis. As MCR and TDV were determined separately, only two constants (kd, k~p) were available to fit Model I and three constants (kd, ksp and k12) to fit Model 2. Model 1 failed to give satisfactory fits in any case (results not shown). When constants were adjusted to fit the tail of the serum insulin response the predicted initial rise was much faster than that observed experimentally. In contrast excellent fits were obtained using Model 2. Computer fits are shown in Figure 5 with the best-fit values of the rate constants. While there was some variation it is clear that kt2 was high in all cases (corresponding to a rapid movement of insulin from pool 1 to pool 2), with k~p largely determining systemic insulin delivery in all but the initial stages following SC insulin administration. It is also of note that the rate constant of insulin degradation kd was < 10%/h in all cases.
Fate of administered insulin. insulin. Approximately 80% of administered insulin had appeared by 4 h with the 5-min infusions (78% in 3.3 U/ml study; 86% in 40 U/ml study). This dropped to 61% for the 30-min infusion. Relatively little (20%-30%) of the continuous low-level SC insulin infusion had appeared in the circulation by 4 h, and it is of note that the estimated systemic entry rate at 4 h is approximately 50% of the SC infusion rate of 40mU/min (2.4 U/h). Figure 7 shows estimates of mean degradation and local accumulation of insulin. A distinction between these is necessarily imprecise. However, the best-fit value for total insulin degraded over the 4-h period was < 20% of administered insulin in all cases.
Discussion
While mathematical models have been proposed for the systemic handling of IV infused insulin [12, 13] , there are no counterparts for the more complex situation of continuous SC insulin infusion. A monoexponential decay curve may be adequate to fit some [2, 14] but not all [1, 3] data on disappearance of trace radiolabelled insulin following bolus injection. Our simple model (Model 1), which assumes that all SC-administered insulin is available for immediate transcapillary absorption, would not fit serum insulin response to SC insulin infusion. In particular Model 1 does not account for an initial time lag (t~ of 8-24 min -calculated from k12 in Model 2 of 180% to 550%/h). The split-pool model of SC insulin kinetics (Model 2) takes into account the initial absorption delay and gives a good fit to mean serum insulin curves following a variety of SC inputs.
Prior quantitation of MCR and TDV of insulin by IV infusion allows systemic insulin delivery rates to be estimated directly from serum insulin response curves. This method is not affected by possible local SC degradation of insulin [3] . However, interpretation is based on the assumption that the SC route does not alter biological activity of insulin without a corresponding change in immunological activity. Supporting this assumption is the equivalent degree of blood glucose suppression observed during prolonged infusion via the two routes [18] . Values for MCR and TDV found here agree well with other values reported [12, 15] . Nevertheless, it is important to obtain specific values of MCR and TDV in individual subjects. A preliminary theoretical analysis [16] , made when only literature values [15] were available, resulted in overestimation of SC insulin degradation.
Our results, taken with previously reported data, demonstrate a slight but significant delay (15-20 min) in SC insulin absorption with increased concentration. This was reflected in Model 2 by a reduction in k12 suggesting a delay in the movement of insulin to a region allowing transcapillary absorption. Clinically allowance could be made for use of more concentrated insulin by commencing the meal pulse about 15 min before the meal rather than coincident with the meal(s) [5] . In further studies (not shown) we have found that the absorption delay associated with 100U/ml compared with 40 U/ml insulin could be almost exactly offset by bolus rather than 5-min delivery.
There was some variation in model parameters (k12, ksp and kd) according to the SC insulin input. Nevertheless some consistent patterns emerge. The constant k12, which largely determines the initial rate of increase of serum insulin, is large, varying from 180% to 550%/h. The constant ksp, which has an increasing influence on serum insulin levels over the later time course, is lower, varying from 20% to 60%. The half-time (t~) of removal of insulin from pool 2 (given by 70/ksp ) is approximately 70 rain for the rapid 5-rain infusions, agreeing well with mean estimates of t,n for disappearance of radiolabelled insulin following abdominal bolus administration of 87 min [1] , 76 min [2] and 120 min [14] . We estimate approximately 80% (78%-86%) of SC insulin is absorbed over 4 h following rapid SC infusions.
Our results however suggest a reduction in absorption rate constant (increase in half-life) during prolonged delivery at lower rates (simulated basal delivery); during infusion of 2.4 U/h of 40 U/ml insulin, Systemic insulin delivery was only about 1.2 U/h after 4 h. This appeared to increase marginally but not significantly with pulsatile administration. The rate of 2.4 U/h was moderately above the usual basal rate for CSII, but was chosen to produce serum insulin levels which could be measured with reasonable precision.
Variation of the model constants according to the type of input infusion suggests that the linear model is an oversimplification, and indicates directions for improvement. For example, there may be some local reversible binding of insulin delaying absorption at low infusion rates, with saturation of the binding at high infusion rates.
Another consistent pattern which has emerged is the low rate (best fit, K~ < 10%/h) of SC degradation re-gardless of SC input. The extent of SC degradation in man has not been clear [21] [22] [23] . In our studies concentration of SC insulin infused had little effect on SC insulin degradation. While the distinction between locally degraded and accumulated insulin is necessarily imprecise, our best-fit parameters correspond to < 20% total degradation of SC administered insulin over the 4-h period. Thus the slow initial rate of systemic delivery of insulin associated with prolonged (basal) infusion is associated with local accumulation rather than degradation or irreversible loss of SC insulin. This is consistent with considerable differences in response to matched infusions of SC and IV insulin over 1-2 h [17] , but with steady state insulin levels during 8-h SC infusions of approximately 80% of that produced by IV infusion [18] .
A limitation to our study has been the restriction of modelling studies to mean responses for each SC input rather than fitting individual responses. This practice has previously been used in modelling to identify characteristics defining an 'average' person [19] ; studies on a larger group of subjects will be necessary to analyse individual variation. Also results are reported only in normal subjects and responses may differ in the diabetic population. Nevertheless preliminary studies in insulindependent diabetes, using free insulin levels suggest that SC degradation is no greater than in normal subjects [20] .
In conclusion, kinetic modelling is a useful way of quantitating systemic appearance of SC insulin and provides a rational basis for examining the fate of SC infused insulin and its relationship to patterns of administration. This information should be particularly useful in programming the second-generation devices for CSII which are now becoming available. For example a relatively long time delay (t,~ of 3-4 h) in systemic insulin delivery following changes in basal SC delivery rate should be taken into account, particularly when commencing or resuming interrupted CSII therapy.
